This year marks Novo Nordisk’s 30th anniversary in China, and it could also be the year the company's red-hot weight loss injection Wegovy (semaglutide) wins approval in the populous East Asian nation that’s increasingly grappling with diseases like obesity and diabetes.
Now, Novo is returning to its roots with an expansion of the flagship Chinese medicines factory it opened in Tianjin, China, back in 1994.
